Seniors' prescription drug cost inflation and cost containment: evidence from British Columbia.
暂无分享，去创建一个
[1] S. Morgan. Quantifying components of drug expenditure inflation: the British Columbia seniors' drug benefit plan. , 2002, Health services research.
[2] S. Schneeweiss,et al. Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization , 2022 .
[3] S. Schneeweiss,et al. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. , 2002, The New England journal of medicine.
[4] Mark Zezza,et al. Health spending projections for 2001-2011: the latest outlook. , 2002, Health affairs.
[5] Clyde Hertzman,et al. APOCALYPSE NO: Population Aging and The Future of Health Care Systems , 2001, Canadian Journal on Aging / La Revue canadienne du vieillissement.
[6] J. Iglehart. Revisiting the Canadian health care system. , 2000, The New England journal of medicine.
[7] A. Chawla,et al. Explaining drug spending trends: does perception match reality? , 2000, Health affairs.
[8] N. Roos,et al. What is right about the Canadian health care system? , 1999, The Milbank quarterly.
[9] F. Peys,et al. The demographic impact on ambulatory pharmaceutical expenditure in Belgium. , 1998, Health policy.
[10] C. Schur,et al. Prescription drug spending: the impact of age and chronic disease status. , 1997, American journal of public health.
[11] B. O'brien,et al. Financial Incentives to Dispense Low-Cost Drugs: A Case Study of British Columbia Pharmacare , 1996 .